CROI 2023 Tuberculosis Research Round Up
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
TB Treatment Trial Results in Context for Communities
On Tuesday, March 14 at 8:00 am ET, join Treatment Action Group (TAG) and Dr. Jennifer Furin for an overview of key results and breakdown of how they fit into the larger TB policy and research landscapes.
Treatment Action Group Announces Palm Desert Exhibition at Melissa Morgan Fine Art – “35 Years of Art to End AIDS”
Treatment Action Group (TAG) is pleased to present the exhibition “35 Years of Art to End AIDS” at Melissa Morgan Fine Art in Palm Desert, CA. The exhibition features selected works from TAG’s Limited Art Editions Collection and will run from March 17 through April 7.
Community Call to Action on Equitable Access to Long-Acting Therapies
The growing pipeline for long-acting therapies and their potential to accelerate various national and global disease elimination goals warrants global community mobilization to ensure equitable access to these therapies.
Open Letter: Urgent Action Necessary to Improve Equitable Access to Bedaquiline-Based Regimens and Achieve 1/4/6×24
TAG and a coalition of civil society activists, public health leaders, and researchers acting in solidarity with communities affected by tuberculosis sent an open letter to Johnson & Johnson calling on the company to publicly commit to withdraw and not…
2022 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
2022 Report on TB Research Funding Trends
For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worldwide in 2021.
Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health
Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.
1/4/6×24 Community Campaign Training Materials
Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…
TAGline November 2022
This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.